Mirco J. Friedrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mirco J. Friedrich has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Müller-Tidow
University Hospital Heidelberg, Heidelberg, Germany
27 shared publications - Marc Steffen Raab
Department of Hematology, Oncology and Rheumatology Heidelberg University Hospital Heidelberg Germany
26 shared publications - Niels Weinhold
Heidelberg Myeloma Center and GMMG Study Group, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
25 shared publications - Niklas Kehl
Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg Heidelberg, Germany
25 shared publications - Christine Riedhammer
University Hospital of Würzburg 3 Department of Internal Medicine II Würzburg, Germany
24 shared publications - Christoph Schaefers
Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology University Medical Center Hamburg‐Eppendorf Hamburg Germany
24 shared publications
Latest Publications
- Open Access
+A CAR T cell-amplified suppressive B cell circuit in AML
Immunotherapy in acute myeloid leukemia (AML) is constrained by a hostile bone marrow niche. Here we identify atypical memory B cells (B atyp ) as a suppressive population within this microenvironment. Across single cell and flow cytometry cohorts, B atyp were expanded in AML, and their molecular and phenotypic profiles resembled those of atypical B cells associated with chronic inflammatory conditions. B atyp were polarized within the AML microenvironment, and this was amplified by CAR T cell–AML interactions. Mechanistically, polarization was dependent on Toll-like receptor, interferon and CD70–CD27 signaling. B atyp suppressed T cell and CAR T cell responses via PD-1-and TGF-β-R signaling, and were enriched in non-responding patients with AML and myeloma. CD180-directed CAR T cells, targeting an antigen shared by B atyp and AML blasts, resisted suppression in vitro and cleared disease in B cell–humanized xenografts while sparing hematopoietic stem cells, with B cell engagement further enhancing their expansion. CAR T cells thus reinforce their own suppressive niche through B atyp polarization, a constraint that can be relieved by dual blast- and B cell-targeting strategies.
Open Access+A CAR T cell-amplified suppressive B cell circuit in AML
Immunotherapy in acute myeloid leukemia (AML) is constrained by a hostile bone marrow niche. Here we identify atypical memory B cells (B atyp ) as a suppressive population within this microenvironment. Across single cell and flow cytometry cohorts, B atyp were expanded in AML, and their molecular and phenotypic profiles resembled those of atypical B cells associated with chronic inflammatory conditions. B atyp were polarized within the AML microenvironment, and this was amplified by CAR T cell–AML interactions. Mechanistically, polarization was dependent on Toll-like receptor, interferon and CD70–CD27 signaling. B atyp suppressed T cell and CAR T cell responses via PD-1-and TGF-β-R signaling, and were enriched in non-responding patients with AML and myeloma. CD180-directed CAR T cells, targeting an antigen shared by B atyp and AML blasts, resisted suppression in vitro and cleared disease in B cell–humanized xenografts while sparing hematopoietic stem cells, with B cell engagement further enhancing their expansion. CAR T cells thus reinforce their own suppressive niche through B atyp polarization, a constraint that can be relieved by dual blast- and B cell-targeting strategies.
- Open Access
- 30 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3224-3234
Clinical decision support in hematological malignancies using a case-grounded AI agent
Multidisciplinary tumor boards integrate longitudinal treatment histories, molecular profiling and rapidly evolving evidence to guide decisions in hematological malignancies, yet access to this level of subspecialty deliberation is increasingly uneven. Here we develop HemaGuide, a locally deployable, modular large language model agent that converts unstructured clinical documents into structured case representations, autonomously routes cases to specialized decision modes (‘guideline’, ‘advanced’ and ‘molecular’) and grounds recommendations in disease-specific guideline flowcharts and a clinical decision memory of >2,000 real-world tumor board cases. In expert-blinded benchmarking on 45 high-complexity cases across six foundation models, HemaGuide substantially improved concordance with tumor board decisions. A systematic ablation study across 11 layers confirmed that performance gains were routing-type-dependent, with no single component sufficient across case types. Automated classification of 70 clinically relevant missense variants showed high concordance with expert standards; no oncogenic variant was downgraded to benign and the whole workflow was completed under real-time conditions on commodity hardware with a median latency of 39 s rather than the hours typically required for manual molecular board workflows. In a simulated practice study, agent-assisted resident physicians achieved near-senior concordance and partially outperformed senior physicians in their subspecialty. External validation on 555 independent cases from a second academic center yielded 81.8% concordance across 47 entities, and a prospective 1-month silent trial on 64 consecutive, unselected cases achieved 82.8% concordance. Hallucinations occurred in 2 of 664 evaluated cases (0.3%). Together these data provide evidence that locally deployable, case-grounded large language model agents can deliver auditable clinical decision support across hematological malignancies, with concordance maintained across institutions and under real-time conditions on commodity hardware.
- 30 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3224-3234
Open AccessClinical decision support in hematological malignancies using a case-grounded AI agent
Multidisciplinary tumor boards integrate longitudinal treatment histories, molecular profiling and rapidly evolving evidence to guide decisions in hematological malignancies, yet access to this level of subspecialty deliberation is increasingly uneven. Here we develop HemaGuide, a locally deployable, modular large language model agent that converts unstructured clinical documents into structured case representations, autonomously routes cases to specialized decision modes (‘guideline’, ‘advanced’ and ‘molecular’) and grounds recommendations in disease-specific guideline flowcharts and a clinical decision memory of >2,000 real-world tumor board cases. In expert-blinded benchmarking on 45 high-complexity cases across six foundation models, HemaGuide substantially improved concordance with tumor board decisions. A systematic ablation study across 11 layers confirmed that performance gains were routing-type-dependent, with no single component sufficient across case types. Automated classification of 70 clinically relevant missense variants showed high concordance with expert standards; no oncogenic variant was downgraded to benign and the whole workflow was completed under real-time conditions on commodity hardware with a median latency of 39 s rather than the hours typically required for manual molecular board workflows. In a simulated practice study, agent-assisted resident physicians achieved near-senior concordance and partially outperformed senior physicians in their subspecialty. External validation on 555 independent cases from a second academic center yielded 81.8% concordance across 47 entities, and a prospective 1-month silent trial on 64 consecutive, unselected cases achieved 82.8% concordance. Hallucinations occurred in 2 of 664 evaluated cases (0.3%). Together these data provide evidence that locally deployable, case-grounded large language model agents can deliver auditable clinical decision support across hematological malignancies, with concordance maintained across institutions and under real-time conditions on commodity hardware.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S4.Complications and toxicities – CAR-HEMATOTOX (HTX) < 3 vs. ≥ 3
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S4.Complications and toxicities – CAR-HEMATOTOX (HTX) < 3 vs. ≥ 3
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S8. Cytopenias before and during treatment and associated supportive measures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S8. Cytopenias before and during treatment and associated supportive measures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S7. Multivariable logistic regression analyses: Hospitalization ≥ 14 days
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S7. Multivariable logistic regression analyses: Hospitalization ≥ 14 days
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S3. Complications and toxicities
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S3. Complications and toxicities
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S10. Cytopenias before and during treatment – m-EASIX ≤ median vs. > median
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S10. Cytopenias before and during treatment – m-EASIX ≤ median vs. > median
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S17 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S17. Multivariable Cox regression analyses: Progression-free survival
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S17 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S17. Multivariable Cox regression analyses: Progression-free survival
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S16. Univariable Cox regression analysis: Overall survival
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S16. Univariable Cox regression analysis: Overall survival
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S5. Complications and toxicities – m-EASIX ≤ median vs. > median
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S5. Complications and toxicities – m-EASIX ≤ median vs. > median